NCT04921358 2025-06-29Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerBeiGenePhase 3 Terminated377 enrolled 22 charts
NCT05461794 2025-06-13Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell CarcinomaBeiGenePhase 2 Terminated96 enrolled 17 charts
NCT03666143 2024-11-04A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Participants With Advanced Solid TumorsBeiGenePhase 1 Completed216 enrolled 20 charts
NCT03941873 2024-10-26A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction CancerBeiGenePhase 1/2 Completed111 enrolled 22 charts
NCT04472650 2024-10-26Relative Bioavailability of Two Different Capsule Formulations of Sitravatinib in Healthy AdultsBeiGenePhase 1 Completed26 enrolled 14 charts
NCT02954991 2024-04-22Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung CancerMirati Therapeutics Inc.Phase 2 Terminated161 enrolled 15 charts
NCT03606174 2023-08-24A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial CarcinomaMirati Therapeutics Inc.Phase 2 Terminated260 enrolled 28 charts